Biotech · Public company · Brisbane, CA, US
Annexon, Inc.
Ticker ANNX · SEC CIK 0001528115
Track this companyFree. Adds Annexon, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials93 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline12
- Sham AdministrationPhase 3 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- TanruprubartPhase 3 · Guillain-Barre SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- VonaprumentPhase 3 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- ANX005Phase 2 · Warm Autoimmune Hemolytic Anemia (wAIHA)ClinicalTrials.gov · fetched Nov 12, 2026
- ANX005Phase 2 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- ANX005Phase 2 · Huntington DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ANX007Phase 2 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- Sham comparatorPhase 2 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- 2.5mg ANX007Phase 1 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- 5.0mg ANX007Phase 1 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- ANX007Phase 1 · Open-angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 1 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)PHASE3 · NOT_YET_RECRUITING · started Sep 30, 2026ClinicalTrials.gov NCT07807969 · fetched Nov 12, 2026
- An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)PHASE3 · RECRUITING · started Sep 12, 2025ClinicalTrials.gov NCT07020819 · fetched Nov 12, 2026
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 30, 2024ClinicalTrials.gov NCT06510816 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)PHASE2 · COMPLETED · started Nov 10, 2021ClinicalTrials.gov NCT04691570 · fetched Nov 12, 2026
- A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyPHASE2 · COMPLETED · started Feb 26, 2021ClinicalTrials.gov NCT04656561 · fetched Nov 12, 2026
- Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)PHASE2 · COMPLETED · started Jan 15, 2021ClinicalTrials.gov NCT04569435 · fetched Nov 12, 2026
- An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's DiseasePHASE2 · COMPLETED · started Sep 29, 2020ClinicalTrials.gov NCT04514367 · fetched Nov 12, 2026
- Study of ANX007 in Participants With Primary Open-angle GlaucomaPHASE1 · COMPLETED · started Jul 25, 2018ClinicalTrials.gov NCT04188015 · fetched Nov 12, 2026
- Single-dose Study of ANX007 in Participants With Primary Open-angle GlaucomaPHASE1 · COMPLETED · started Mar 23, 2018ClinicalTrials.gov NCT03488550 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026